Tirzepatide vs Semaglutide

Quick verdict: Tirzepatide vs Semaglutide is the defining comparison in modern incretin pharmacotherapy. Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 receptor agonist, while semaglutide (Ozempic/Wegovy) is a selective GLP-1 receptor agonist. In head-to-head trial data (SURPASS-2), tirzepatide produced greater HbA1c reductions and weight loss than semaglutide 1 mg in type 2 diabetes.[1][2] For weight management, tirzepatide’s SURMOUNT programme reported up to 22.5% mean weight loss versus semaglutide’s ~14.9% in STEP 1 — though these are cross-trial comparisons, not direct head-to-head obesity data.[3][4] Semaglutide has the stronger cardiovascular evidence base, with the landmark SELECT trial demonstrating a 20% reduction in major adverse cardiovascular events.[5] The practical differentiator: tirzepatide’s dual mechanism may produce greater weight and glycaemic effects, while semaglutide has deeper long-term safety data and proven cardiovascular outcomes.

Read the full peptide profiles: Tirzepatide and Semaglutide.

At a Glance: Tirzepatide vs Semaglutide

How They Work

Tirzepatide and semaglutide both belong to the incretin-based peptide class but engage the gut-brain metabolic axis through different receptor configurations. Semaglutide is a selective GLP-1 receptor agonist: it mimics the human GLP-1 hormone, suppressing appetite through hypothalamic signalling, slowing gastric emptying, and enhancing glucose-dependent insulin secretion. Its structural modifications — a C18 fatty acid side chain and DPP-4-resistant amino acid substitutions — extend its half-life to approximately one week, enabling once-weekly administration.[4][5]

Tirzepatide adds a second receptor target. As a dual GIP/GLP-1 agonist — sometimes called a “twincretin” — it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. Tirzepatide is an imbalanced agonist, showing stronger GIP-receptor activity relative to its GLP-1 activity. The GIP component is thought to contribute additive metabolic effects: enhanced insulin sensitivity, potentially different adipose tissue signalling, and complementary satiety pathways that may explain the differentiated clinical outcomes observed in head-to-head comparison.[1][2][6]

The engineering distinction matters practically: semaglutide optimises a single, well-characterised pathway; tirzepatide coordinates two receptor systems for potentially greater metabolic effect. Both preserve the incretin-mimetic approach — working through endogenous hormonal pathways rather than bypassing physiological regulation. For the next-generation approach adding a third receptor, see Retatrutide vs Tirzepatide.

Evidence Comparison

Semaglutide currently has the deeper and broader clinical evidence base. The STEP programme (weight management), SUSTAIN programme (T2D), and the landmark SELECT cardiovascular outcomes trial collectively provide thousands of patient-years of data across multiple populations and endpoints. SELECT is particularly significant: this 17,604-patient RCT demonstrated a 20% reduction in major adverse cardiovascular events in people with obesity and established cardiovascular disease — the first trial to show cardiovascular benefit from a GLP-1 agonist independent of diabetes status.[5] Additional data spans kidney outcomes, heart failure (HFpEF), and knee osteoarthritis.[4]

Tirzepatide’s evidence base is newer but rapidly expanding. The SURPASS programme (T2D) includes SURPASS-2, which directly compared tirzepatide to semaglutide 1 mg and showed tirzepatide producing greater HbA1c reductions and weight loss.[2] The SURMOUNT programme (obesity) reported up to 22.5% mean weight loss at 72 weeks — numerically greater than semaglutide’s STEP results, though cross-trial comparisons carry inherent limitations.[3] A dedicated cardiovascular outcomes trial for tirzepatide is ongoing but not yet reported, which is the most significant evidence gap relative to semaglutide.

The critical caveat: SURPASS-2 compared tirzepatide against semaglutide 1 mg (Ozempic), not the higher 2.4 mg dose used in Wegovy for weight management. A true head-to-head weight-loss comparison at optimal doses of both compounds has not been published. The tirzepatide advantage in weight loss is directionally consistent across data sources but awaits definitive direct comparison.[1][2][3]

When Each Fits Better

Tirzepatide may be a stronger fit when:

• Maximum weight reduction is the primary research endpoint — tirzepatide has demonstrated numerically greater weight loss across available data[3]
• Dual receptor engagement is desired — the GIP component may provide additive metabolic effects beyond GLP-1 alone[6]
• Glycaemic control with greater HbA1c reduction is prioritised — tirzepatide outperformed semaglutide 1 mg in SURPASS-2[2]
• Sleep apnoea-related outcomes are relevant — SURMOUNT-OSA data suggests meaningful OSA severity reduction[3]

Semaglutide may be a stronger fit when:

• Cardiovascular risk reduction is a primary consideration — SELECT provides the strongest CV outcomes data in the GLP-1 class[5]
• Long-term safety data depth is important — semaglutide has more years of post-marketing surveillance and longer-duration trials
• Oral administration is preferred — Rybelsus (oral semaglutide) and high-dose OASIS formulations offer a non-injectable option[4]
• Kidney or heart failure endpoints are relevant — SELECT sub-analyses and dedicated HFpEF data extend semaglutide’s evidence breadth

Head-to-Head

The only published direct comparison is SURPASS-2, a Phase 3 trial in type 2 diabetes. Tirzepatide at all three dose levels (5 mg, 10 mg, 15 mg) produced superior HbA1c reductions and weight loss compared to semaglutide 1 mg. The highest tirzepatide dose achieved approximately 2.3% HbA1c reduction and 12.4 kg weight loss versus 1.9% and 6.2 kg for semaglutide. These differences were statistically significant.[2]

However, this comparison has limitations. Semaglutide 1 mg is the T2D dose (Ozempic), not the 2.4 mg weight-management dose (Wegovy). Cross-trial comparisons between SURMOUNT (tirzepatide) and STEP (semaglutide) suggest tirzepatide maintains a weight-loss advantage (~22.5% vs ~14.9%), but trial populations, durations, and designs differ. Retrospective analyses and network meta-analyses generally support tirzepatide’s greater weight-loss efficacy, but definitive head-to-head obesity data at optimised doses is still pending.[1][3][7]

On tolerability, both compounds share a similar GI side-effect profile — nausea, diarrhoea, vomiting, constipation — predominantly during dose escalation. The rates appear broadly comparable across their respective programmes, with no clear tolerability advantage for either compound. Where semaglutide currently leads is in breadth of indication: approved for T2D, obesity, and with demonstrated cardiovascular benefit, while tirzepatide’s CV outcomes data is still accumulating.[2][5]

FAQ

Is tirzepatide more effective than semaglutide for weight loss?

Based on available data, tirzepatide appears to produce greater weight loss than semaglutide. SURMOUNT-1 reported up to 22.5% mean weight loss with tirzepatide versus ~14.9% with semaglutide in STEP 1.[3][4] However, these are cross-trial comparisons. The only direct head-to-head (SURPASS-2) used semaglutide at a lower dose than its weight-management formulation. A definitive direct comparison at optimal weight-loss doses remains unpublished.

Does semaglutide have better cardiovascular evidence?

Yes. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide in people with obesity — the first GLP-1 agonist to show cardiovascular benefit independent of diabetes status.[5] Tirzepatide’s cardiovascular outcomes trial is ongoing but not yet reported. This is currently semaglutide’s most significant evidence advantage.

Can you take tirzepatide and semaglutide together?

Combining two incretin-class agents is not supported by clinical evidence. Both compounds activate GLP-1 receptors, so combination use would risk overlapping pharmacology, additive GI side effects, and no established efficacy rationale. Clinical guidelines do not recommend concurrent use of multiple GLP-1 pathway agonists.

Which has fewer side effects — tirzepatide or semaglutide?

Both compounds share similar GI-predominant side-effect profiles: nausea, diarrhoea, vomiting, and constipation, primarily during dose escalation. Cross-trial incidence rates are broadly comparable, with no clear tolerability advantage for either compound. Individual response varies, and tolerability should be evaluated personally rather than assumed from population-level data.[2][3]

What about retatrutide — is it better than both?

Retatrutide is a triple GIP/GLP-1/glucagon agonist in Phase 3 trials, with Phase 2 data showing up to 24.2% weight loss at 48 weeks — numerically exceeding both tirzepatide and semaglutide. However, retatrutide is investigational with no FDA approval and much less safety data. See Retatrutide vs Tirzepatide for the full comparison.[8]

References

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024.
2. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. PMID: 34170647.
3. Jastreboff AM, et al. Tirzepatide for obesity — SURMOUNT-4 continued treatment versus placebo. JAMA. 2024;331(1):38-48. PMID: 37952131.
4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. PMID: 33567185.
5. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232. PMID: 37385275.
6. Min T, et al. Tirzepatide — a dual GIP/GLP-1 receptor agonist: mechanism and clinical evidence. Endocrinology. 2022;163(6):bqac057. PMID: 33068776.
7. Davies MJ, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984. PMID: 28563169.
8. Jastreboff AM, et al. Retatrutide Phase 2 obesity trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.